1. Ocular surface disease in thyroid eye disease: A narrative review
   Harkaran S. Rana et al, 2022, The Ocular Surface CrossRef
2. Immunophenotype of Lacrimal Glands in Graves Orbitopathy: Implications for the Pathogenesis of Th1 and Th17 Immunity
   Yazhuo Huang et al, 2022, Thyroid CrossRef
3. Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves’ orbitopathy
   Mariya Asenova Stoynova et al, 2023, International Ophthalmology CrossRef
4. Yiqi Jiedu herbal decoction attenuates the 2 Gy 60Co γ ray induced spleen injury by inhibiting apoptosis and modulating the immune balance
   An Wang et al, 2022, Journal of Ethnopharmacology CrossRef
5. Looking Beyond Th17 Cells: A Role for Th17.1 Cells in Thyroid-associated Ophthalmopathy?
   Minmin Jiang et al, 2023, Endocrinology CrossRef
6. Graves' ophthalmopathy and dry eye syndrome
   Edoardo APPOLLONI et al, 2023, Minerva Ophthalmology CrossRef
7. A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy
   Zhangfang Li et al, 2023, The Journal of Clinical Endocrinology & Metabolism CrossRef
8. Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves’ Orbitopathy
   Jun Jia et al, 2022, Frontiers in Pharmacology CrossRef
9. Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy
   Kenneth K. H. Lai et al, 2023, Journal of Clinical Medicine CrossRef
10. Identification of potential immunotherapeutic targets and prognostic biomarkers in Graves' disease using weighted gene co-expression network analysis
    Nianrong Mi et al, 2024, Heliyon CrossRef